British Pharmacopoeia 1993. Addendum 1997 PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download British Pharmacopoeia 1993. Addendum 1997 PDF full book. Access full book title British Pharmacopoeia 1993. Addendum 1997 by British pharmacopoeia commission. Download full books in PDF and EPUB format.
Author: British pharmacopoeia commission
Publisher:
ISBN: 9780113219933
Category :
Languages : en
Pages : 284
Get Book Here
Book Description
Author: British pharmacopoeia commission
Publisher:
ISBN: 9780113219933
Category :
Languages : en
Pages : 284
Get Book Here
Book Description
Author: Anthony C. Cartwright
Publisher: Routledge
ISBN: 1317039793
Category : History
Languages : en
Pages : 266
Get Book Here
Book Description
The British Pharmacopoeia has provided official standards for the quality of substances, medicinal products and articles used in medicine since its first publication in 1864. It is used in over 100 countries and remains an essential global reference in pharmaceutical research and development and quality control. This book explores how these standards have been achieved through a comprehensive review of the history and development of the pharmacopoeias in the UK, from the early London, Edinburgh and Dublin national pharmacopoeias to the creation of the British Pharmacopoeia and its evolution over 150 years. Trade in medicinal substances and products has always been global, and the British Pharmacopoeia is placed in its global context as an instrument of the British Empire as it first sought to cover the needs of countries such as India and latterly as part of its role in international harmonisation of standards in Europe and elsewhere. The changing contents of the pharmacopoeias over this period reflect the changes in medical practice and the development of dosage forms from products dispensed by pharmacists to commercially manufactured products, from tinctures to the latest monoclonal antibody products. The book will be of equal value to historians of medicine and pharmacy as to practitioners of medicine, pharmacy and pharmaceutical analytical chemistry.
Author: Av Yadav
Publisher: Pragati Books Pvt. Ltd.
ISBN: 9788185790411
Category : Fiction
Languages : en
Pages : 232
Get Book Here
Book Description
Introduction to Pharmaceutics and its Scope - Development of a New Drug - Introduction to Dosage Forms of Drugs - History and Development of Profession of Pharmacy - Introduction to Pre-formulation - Biopharmaceutics - Good Manufacturing Practices - Introduction to Pre-formulation - Biopharmaceutics - Good Manufacturing Practices - Introduction to Alternative Systems of Medicines - Drug Delivery Systems - Biological Products - Packaging of Pharmaceuticals - Bibliography - Index
Author: Shein-Chung Chow
Publisher: CRC Press
ISBN: 135111025X
Category : Medical
Languages : en
Pages : 4031
Get Book Here
Book Description
Since the publication of the first edition in 2000, there has been an explosive growth of literature in biopharmaceutical research and development of new medicines. This encyclopedia (1) provides a comprehensive and unified presentation of designs and analyses used at different stages of the drug development process, (2) gives a well-balanced summary of current regulatory requirements, and (3) describes recently developed statistical methods in the pharmaceutical sciences. Features of the Fourth Edition: 1. 78 new and revised entries have been added for a total of 308 chapters and a fourth volume has been added to encompass the increased number of chapters. 2. Revised and updated entries reflect changes and recent developments in regulatory requirements for the drug review/approval process and statistical designs and methodologies. 3. Additional topics include multiple-stage adaptive trial design in clinical research, translational medicine, design and analysis of biosimilar drug development, big data analytics, and real world evidence for clinical research and development. 4. A table of contents organized by stages of biopharmaceutical development provides easy access to relevant topics. About the Editor: Shein-Chung Chow, Ph.D. is currently an Associate Director, Office of Biostatistics, U.S. Food and Drug Administration (FDA). Dr. Chow is an Adjunct Professor at Duke University School of Medicine, as well as Adjunct Professor at Duke-NUS, Singapore and North Carolina State University. Dr. Chow is the Editor-in-Chief of the Journal of Biopharmaceutical Statistics and the Chapman & Hall/CRC Biostatistics Book Series and the author of 28 books and over 300 methodology papers. He was elected Fellow of the American Statistical Association in 1995.
Author: Stationery Office (Great Britain)
Publisher:
ISBN:
Category : Government publications
Languages : en
Pages : 596
Get Book Here
Book Description
Author: Rolf Franke
Publisher: CRC Press
ISBN: 0203022386
Category : Health & Fitness
Languages : en
Pages : 306
Get Book Here
Book Description
For over 2000 years, preparations of chamomile flowers have counted among the medicinal treasures of many cultural groups. This book provides an interdisciplinary inventory of the scientific level of knowledge about German chamomile as well as Roman chamomile, the two types of chamomile most produced. It includes information for pharmacists and the
Author: Stationery Office Staff
Publisher:
ISBN: 9780115005145
Category :
Languages : en
Pages : 588
Get Book Here
Book Description
Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN:
Category : Medical
Languages : en
Pages : 692
Get Book Here
Book Description
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.
Author:
Publisher:
ISBN:
Category : Carcinogenesis
Languages : en
Pages : 686
Get Book Here
Book Description
Author:
Publisher:
ISBN:
Category : Civil service
Languages : en
Pages : 572
Get Book Here
Book Description
